Abstract
Tigecycline is an alternative antibiotic for managing carbapenem-resistant Gram-negative bacterial infections. However, disk diffusion and automated testing often show false-intermediate or false-resistant results in tigecycline susceptibility, misleading clinical antimicrobial therapy. Broth microdilution (BMD) is the reference method for testing tigecycline susceptibility, but it is labor intensive and time consuming to perform in clinical laboratories. Therefore, a simple and accurate method is urgently needed. We evaluated the performance of VITEK 2, E-test, Kirby–Bauer disk diffusion (KB), and modified KB disk diffusion (mKB) versus BMD in testing tigecycline susceptibility of 372 strains of carbapenem-resistant Klebsiella pneumoniae (CRKP) and 346 strains of carbapenem-resistant Acinetobacter baumannii (CRAB). BMD confirmed that 96.8% of CRKP and 91% of CRAB strains were susceptible to tigecycline. E-test, VITEK 2, KB, and mKB yielded categorical agreement of 96.7/59.3%, 69.9/54.3%, 78.5/87.3%, and 96.5%/91% for CRKP/CRAB, respectively. No very major error was found for either CRKP or CRAB by any method. No major error was found for CRKP or CRAB by the mKB method. The mKB method enhanced by R-buffer is simple, accurate, and inexpensive for clinical laboratories to test the susceptibility of CRKP and CRAB isolates to tigecycline.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Logan LK, Weinstein RA (2017) The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 215(suppl_1):S28–S36
Geng TT, Xu X, Huang M (2018) High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study. Medicine (Baltimore) 97(8):e9961
Ni W, Han Y, Liu J et al (2016) Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore) 95(11):e3126
Grandesso S, Sapino B, Amici G et al (2014) Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii? New Microbiol 37(4):503–508
Idelevich EA, Büsing M, Mischnik A et al (2016) False non-susceptible results of tigecycline susceptibility testing against Enterobacteriaceae by an automated system: a multicentre study. J Med Microbiol 65(8):877–881
Lo-Ten-Foe JR, de Smet AM, Diederen BM et al (2007) Comparative evaluation of the VITEK 2, disk diffusion, E-test, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including hetero resistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob Agents Chemother 51(10):3726–3730
Jones RN, Ferraro MJ, Reller LB et al (2007) Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 45(1):227–230
Clinical and Laboratory Standards Institute (2019) Performance standards for antimicrobial susceptibility testing. 29th edn. CLSI supplement M100. Wayne, America
Zhang J, Zhao C, Chen H et al (2015) Comparative evaluation of tigecycline susceptibility testing methods for Acinetobacter baumannii and Enterobacteriaceae. J Glob Antimicrob Resist 3(2):75–79
Sheng ZK, Hu F, Wang W et al (2014) Mechanisms of tigecycline resistance among Klebsiella pneumoniae clinical isolates. Antimicrob Agents Chemother 58:6982–6985
Villa L, Feudi C, Fortini D, Garcia-Fernandez A, Carattoli A (2014) Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance. Antimicrob Agents Chemother 58:1707–1712
Ahn C, Yoon SS, Yong TS et al (2016) The resistance mechanism and clonal distribution of tigecycline-nonsusceptible Klebsiella pneumoniae isolates in Korea. Yonsei Med J 57:641–646
Nielsen LE, Snesrud EC, Onmus-Leone F et al (2014) IS5 element integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 58:6151–6156
Clinical and Laboratory Standards Institute (2015) Verification of commercial microbial identification and antimicrobial susceptibility testing systems. 1st edn. CLSI guideline M52. Wayne, America
Funding
This work was supported by the National Mega-project for Innovative Drugs (2019ZX09721001-006-004), Shanghai Antimicrobial Surveillance Network (3030231003), and CHINET Antimicrobial Surveillance Network (2020QD049).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yin, D., Guo, Y., Li, M. et al. Performance of VITEK 2, E-test, Kirby–Bauer disk diffusion, and modified Kirby–Bauer disk diffusion compared to reference broth microdilution for testing tigecycline susceptibility of carbapenem-resistant K. pneumoniae and A. baumannii in a multicenter study in China. Eur J Clin Microbiol Infect Dis 40, 1149–1154 (2021). https://doi.org/10.1007/s10096-020-04123-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-020-04123-z